Loading...
In 2020, researchers at Imperial College London published a landmark study in the New England Journal of Medicine. The SAMSON trial enrolled 60 statin patients who had quit the drug due to intolerable side effects—muscle pain, fatigue, brain fog. For twelve months, participants cycled through four months each of statins, placebos, and no pills, rating their symptoms daily on a smartphone app. The results stunned the medical community. Patients reported nearly identical symptom severity on statins and placebos—15.4 versus 15.3 on a 100-point scale. Taking no pill at all scored 8.0. The side effects weren't caused by the drug. They were caused by taking a pill patients believed could harm them. This wasn't an isolated finding. A 1981 study gave patients inert sugar pills but warned half a...
Popular framing: Some patients are dramatic and imagine side effects that aren't real.
Structural analysis: Symptom reports are produced by a feedback loop between expectation, attention, and bodily sensation; informed-consent disclosure is the framing that activates that loop. The regulation designed to protect patients reliably manufactures the very symptoms it warns about — a second-order effect of the warning architecture that no individual physician or patient can opt out of. Same patient, same pill, different label, different symptoms.
Closing this gap matters because it reveals that 'more information' is not always more protective — information is itself a treatment with dose, framing, and delivery effects. As long as the popular model treats side-effect experience as purely pharmacological, the systemic harm from nocebo-inducing consent practices remains invisible and unreformable. The gap also obscures that the fix is a design problem, not a values problem: you can preserve patient autonomy while radically changing how risk information is framed and sequenced.
